72 related articles for article (PubMed ID: 1731051)
1. Preclinical studies on LY237733, a potent and selective serotonergic antagonist.
Foreman MM; Fuller RW; Nelson DL; Calligaro DO; Kurz KD; Misner JW; Garbrecht WL; Parli CJ
J Pharmacol Exp Ther; 1992 Jan; 260(1):51-7. PubMed ID: 1731051
[TBL] [Abstract][Full Text] [Related]
2. 5-Hydroxytryptamine2 receptor antagonist activity of the acid metabolite (1-isopropyl dihydrolysergic acid) of the ergoline ester, sergolexole (LY281067).
Cohen ML; Parli CJ; Fuller RW
J Pharmacol Exp Ther; 1989 Dec; 251(3):1006-11. PubMed ID: 2600800
[TBL] [Abstract][Full Text] [Related]
3. Preclinical pharmacology of a new serotonergic receptor antagonist, LY281067.
Cohen ML; Fuller RW; Kurz KD; Parli CJ; Mason NR; Meyers DB; Smallwood JK; Toomey RE
J Pharmacol Exp Ther; 1988 Jan; 244(1):106-12. PubMed ID: 3335993
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological activity of the isomers of LY53857, potent and selective 5-HT2 receptor antagonists.
Cohen ML; Kurz KD; Mason NR; Fuller RW; Marzoni GP; Garbrecht WL
J Pharmacol Exp Ther; 1985 Nov; 235(2):319-23. PubMed ID: 4057073
[TBL] [Abstract][Full Text] [Related]
5. LY53857, a selective and potent serotonergic (5-HT2) receptor antagonist, does not lower blood pressure in the spontaneously hypertensive rat.
Cohen ML; Fuller RW; Kurz KD
J Pharmacol Exp Ther; 1983 Nov; 227(2):327-32. PubMed ID: 6313898
[TBL] [Abstract][Full Text] [Related]
6. LY215840, a potent 5-hydroxytryptamine (5-HT)2 receptor antagonist, blocks vascular and platelet 5-HT2 receptors and delays occlusion in a rabbit model of thrombosis.
Cohen ML; Robertson DW; Bloomquist WE; Wilson HC
J Pharmacol Exp Ther; 1992 Apr; 261(1):202-8. PubMed ID: 1560366
[TBL] [Abstract][Full Text] [Related]
7. 5-hydroxytryptamine (5-HT)1A receptors and the tail-flick response. I. 8-hydroxy-2-(di-n-propylamino) tetralin HBr-induced spontaneous tail-flicks in the rat as an in vivo model of 5-HT1A receptor-mediated activity.
Millan MJ; Bervoets K; Colpaert FC
J Pharmacol Exp Ther; 1991 Mar; 256(3):973-82. PubMed ID: 1826033
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of LY293284: A 5-HT1A receptor agonist with high potency and selectivity.
Foreman MM; Fuller RW; Rasmussen K; Nelson DL; Calligaro DO; Zhang L; Barrett JE; Booher RN; Paget CJ; Flaugh ME
J Pharmacol Exp Ther; 1994 Sep; 270(3):1270-81. PubMed ID: 7523657
[TBL] [Abstract][Full Text] [Related]
9. Serotonin-induced contraction in porcine coronary artery: use of ergolines to support vascular 5-hydroxytryptamine2-receptor heterogeneity.
Cushing DJ; Cohen ML
J Pharmacol Exp Ther; 1993 Jan; 264(1):193-200. PubMed ID: 8423526
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of serotonin-amplified human platelet aggregation by ketanserin, ritanserin, and the ergoline 5HT2 receptor antagonists-LY53857, sergolexole, and LY237733.
McBride PA; Mann JJ; Nimchinsky E; Cohen ML
Life Sci; 1990; 47(23):2089-95. PubMed ID: 2125095
[TBL] [Abstract][Full Text] [Related]
11. Studies with new ergoline derivatives on the effects of central and peripheral 5-hydroxytryptamine receptors.
Harhammer R; Schäfer U; Ott T
Arzneimittelforschung; 1992 Oct; 42(10):1175-9. PubMed ID: 1472137
[TBL] [Abstract][Full Text] [Related]
12. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological studies with two new ergoline derivatives, the potential antipsychotics LEK-8829 and LEK-8841.
Krisch I; Bole-Vunduk B; Pepelnak M; Lavric B; Ocvirk A; Budihna MV; Sket D
J Pharmacol Exp Ther; 1994 Oct; 271(1):343-52. PubMed ID: 7965734
[TBL] [Abstract][Full Text] [Related]
14. LY215840, a high-affinity 5-HT7 receptor ligand, blocks serotonin-induced relaxation in canine coronary artery.
Cushing DJ; Zgombick JM; Nelson DL; Cohen ML
J Pharmacol Exp Ther; 1996 Jun; 277(3):1560-6. PubMed ID: 8667223
[TBL] [Abstract][Full Text] [Related]
15. Preclinical studies on LY228729: a potent and selective serotonin1A agonist.
Foreman MM; Fuller RW; Leander JD; Benvenga MJ; Wong DT; Nelson DL; Calligaro DO; Swanson SP; Lucot JB; Flaugh ME
J Pharmacol Exp Ther; 1993 Oct; 267(1):58-71. PubMed ID: 8229788
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological properties of the receptor(s) involved in the 5-hydroxytryptamine-induced contraction of the feline middle cerebral artery.
Hamel E; Robert JP; Young AR; MacKenzie ET
J Pharmacol Exp Ther; 1989 Jun; 249(3):879-89. PubMed ID: 2732950
[TBL] [Abstract][Full Text] [Related]
17. Flumezapine, an antagonist of central dopamine and serotonin receptors.
Fuller RW; Mason NR
Res Commun Chem Pathol Pharmacol; 1986 Oct; 54(1):23-34. PubMed ID: 2879325
[TBL] [Abstract][Full Text] [Related]
18. 5-HT2-receptor antagonists: alpha 1- vs. 5-HT2-receptor blocking properties in blood vessels.
Cohen ML; Schenck KW; Kurz KD
J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S25-9. PubMed ID: 2459510
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterization of serotonin-O-carboxymethyl-glycyl-tyrosinamide, a new selective indolic ligand for 5-hydroxytryptamine (5-HT)1B and 5-HT1D binding sites.
Boulenguez P; Chauveau J; Segu L; Morel A; Delaage M; Lanoir J
J Pharmacol Exp Ther; 1991 Dec; 259(3):1360-5. PubMed ID: 1762084
[TBL] [Abstract][Full Text] [Related]
20. The pharmacological characterization of a novel selective 5-hydroxytryptamine1A receptor antagonist, NAD-299.
Johansson L; Sohn D; Thorberg SO; Jackson DM; Kelder D; Larsson LG; Rényi L; Ross SB; Wallsten C; Eriksson H; Hu PS; Jerning E; Mohell N; Westlind-Danielsson A
J Pharmacol Exp Ther; 1997 Oct; 283(1):216-25. PubMed ID: 9336327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
